It has been recently revealed in a report that the new drug developed by Amylin Pharmaceutical Company from San Diego has been given approval by the Food and Drug Administration in the U. S.

It has been further revealed that with the mere decision of the approval being out, the shares of the firm have seen a rise of 17% recently.

The drug shall be available over the counters till February, as revealed by the firm. The drug is actually meant for fighting Type 2 diabetes. The unique feature of the same is that it shall be administered merely 2 times a week.

The drug shall be able to control the blood sugar levels in people suffering from Type 2 diabetes. It shall sure mean the dawn of a new and revolutionary style of treatment for the sufferers, and would give them more freedom to live their lives better.

The firm was able to provide the FDA with enough information about the drug and this is why the drug got an approval. It is going to be safe for use, and can be administered by the diabetic patients. There are other firms which are coming up with similar medicines for controlling diabetes, so there is cut throat competition in this race for now.

There are going to be certain statuary warnings about the drug, which would be meant for people suffering from thyroid.

It is going to be an inject-able drug, and would be given to the patients in controlled twice a week doses. “We are clear to begin the next steps toward bringing the first weekly dose diabetes therapy to the market in the United States”, said the Chief Executive of Amylin Daniel Bradbury.